Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 286 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

286 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

286 programs

Clinical programs

Page 4 of 6

  1. BO43249

    Hoffmann-La Roche

    Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  2. BO43936

    Hoffmann-La Roche

    Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  3. BO44157

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  4. BO44178

    Hoffmann-La Roche

    Previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 other active

    1 trial

  5. BO44426

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. BO45853

    Hoffmann-La Roche

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  7. BP39144

    Hoffmann-La Roche

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  8. BP41072

    Hoffmann-La Roche

    Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)

    phase 2 small molecule active

    1 trial

  9. BP42155

    Hoffmann-La Roche

    Alzheimer's disease

    phase 2 small molecule active

    1 trial

  10. BP42772

    Hoffmann-La Roche

    Advanced or metastatic squamous cell carcinoma of the esophagus

    phase 2 other active

    1 trial

  11. BP44745

    Hoffmann-La Roche

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  12. BP45381

    Hoffmann-La Roche

    BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

    phase 2 small molecule active

    1 trial

  13. BP45703

    Hoffmann-La Roche

    Type 2 Diabetes Mellitus (T2D)

    phase 2 small molecule active

    1 trial

  14. BP46016

    Hoffmann-La Roche

    Progressive Forms of Multiple Sclerosis (PMS)

    phase 2 small molecule active

    1 trial

  15. CN45320

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial

  16. CO40115

    Hoffmann-La Roche

    Metastatic breast cancer, including triple negative breast cancer (TNBC), hormone receptor positive breast cancer (HR+ BC), and HER2 positive and HER2 low breast cancer (HER2+/HER2-low BC)

    phase 2 small molecule active

    1 trial

  17. CO40778

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  18. CO41942

    Hoffmann-La Roche

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  19. CO43476

    Hoffmann-La Roche

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  20. CO43810

    Hoffmann-La Roche

    CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  21. CO43923

    Hoffmann-La Roche

    Multiple Myeloma (MM)

    phase 2 small molecule active

    1 trial

  22. CO45813

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  23. CO46274

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  24. Cetuximab

    Hoffmann-La Roche

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  25. Cobimetinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule completed

    1 trial

  26. Copegus

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 2 small molecule completed

    1 trial

  27. Delandistrogene moxeparvovec-rokl

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  28. Entrectinib

    Hoffmann-La Roche

    Solid Tumors

    phase 2 small molecule active

    1 trial

  29. Entrectinib

    Hoffmann-La Roche

    Breast Cancer

    phase 2 small molecule active

    1 trial

  30. Erlotinib

    Hoffmann-La Roche

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  31. Erlotinib

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  32. GN43271

    Hoffmann-La Roche

    Relapsing Multiple Sclerosis

    phase 2 other active

    1 trial

  33. GO40516

    Hoffmann-La Roche

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  34. GO40554

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  35. GO42216

    Hoffmann-La Roche

    Advanced liver cancers

    phase 2 small molecule active

    1 trial

  36. GO43075

    Hoffmann-La Roche

    Diffuse Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  37. GO44096

    Hoffmann-La Roche

    Solid Tumors

    phase 2 other active

    1 trial

  38. GO45434

    Hoffmann-La Roche

    Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  39. Giredestrant

    Hoffmann-La Roche

    Early Breast Cancer

    phase 2 small molecule completed

    1 trial

  40. Giredestrant

    Hoffmann-La Roche

    Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  41. Idasanutlin

    Hoffmann-La Roche

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  42. ML43332

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  43. Mosunetuzumab

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  44. NP30179

    Hoffmann-La Roche

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  45. NP39488

    Hoffmann-La Roche

    Relapsed/refractory (r/r) B-cell Non-Hodgkin’s Lymphoma (NHL)

    phase 2 other active

    1 trial

  46. Ocrelizumab

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 2 small molecule terminated

    1 trial

  47. P38 Inhibitor (4) 150mg

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  48. Placebo

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.